Shoving Regenxbio aside, Ultragenyx’s Emil Kakkis closes Dimension buyout deal with 400% premium
Ultragenyx $RARE has won its 11th-hour bid for the troubled gene therapy biotech Dimension Therapeutics $DMTX, which is leaving Regenxbio $RGNX at the altar.
Scuttled by a clinical disaster for its hemophilia B program, Dimension was ready to hand over the rest of the pipeline to Regenxbio for $3.41 a share, a hefty premium for its badly battered stock.
But Ultragenyx CEO Emil Kakkis — an adviser to Dimension — clearly felt it still looked like a bargain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.